Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit Mahajan

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Frontiers in Neuroscience|October 31, 2022
Clinical implementation of artificial intelligence in neuroradiology with development of a novel workflow-efficient picture archiving and communication system-based automated brain tumor segmentation and radiomic feature extractionMariam Aboian, Khaled Bousabarah, Eve Kazarian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialHarriet M Kluger, Veronica Chiang, Amit Mahajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain MetastasesSarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Cancers|March 25, 2022
Machine Learning Applications for Differentiation of Glioma from Brain Metastasis-A Systematic ReviewLeon Jekel, Waverly R Brim, Marc von Reppert, et al.
Cancers|August 7, 2021
Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning ModelsXiaoyang Liu, Farhad Maleki, Nikesh Muthukrishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1Sarah A Weiss, Dijana Djureinovic, Shlomit Jessel, et al.
Clinical Endocrinology|August 8, 2015
Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotypeUte I Scholl, James M Healy, Anne Thiel, et al.
The Lancet. Oncology|June 9, 2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trialSarah B Goldberg, Scott N Gettinger, Amit Mahajan, et al.
Molecular Cancer|November 15, 2023
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, et al.
The Lancet. Oncology|April 7, 2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trialSarah B Goldberg, Kurt A Schalper, Scott N Gettinger, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Frontiers in Neuroscience|October 31, 2022
Clinical implementation of artificial intelligence in neuroradiology with development of a novel workflow-efficient picture archiving and communication system-based automated brain tumor segmentation and radiomic feature extractionMariam Aboian, Khaled Bousabarah, Eve Kazarian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialHarriet M Kluger, Veronica Chiang, Amit Mahajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain MetastasesSarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Cancers|March 25, 2022
Machine Learning Applications for Differentiation of Glioma from Brain Metastasis-A Systematic ReviewLeon Jekel, Waverly R Brim, Marc von Reppert, et al.
Cancers|August 7, 2021
Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning ModelsXiaoyang Liu, Farhad Maleki, Nikesh Muthukrishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1Sarah A Weiss, Dijana Djureinovic, Shlomit Jessel, et al.
Clinical Endocrinology|August 8, 2015
Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotypeUte I Scholl, James M Healy, Anne Thiel, et al.
The Lancet. Oncology|June 9, 2016
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trialSarah B Goldberg, Scott N Gettinger, Amit Mahajan, et al.
Molecular Cancer|November 15, 2023
A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily betterDijana Djureinovic, Sarah A Weiss, Irina Krykbaeva, et al.
The Lancet. Oncology|April 7, 2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trialSarah B Goldberg, Kurt A Schalper, Scott N Gettinger, et al.
Pageof 13